FHLC holdings

Computed by this site from the fund's SEC Form N-PORT filing; what the measure does not tell you · every fund in one table · hold it with other funds? X-ray the mix. Pricing: 100% at a quoted market price (level 1), 12 issuer countries.

FHLC's largest investment is Eli Lilly & Co at 12.13% of net assets. Johnson & Johnson and AbbVie Inc follow; the three together are 27.1%. Ten companies are 52.01% of the fund; the other 326 share the rest. Among the 721 equity funds measured here, FHLC behaves like 23.5 holdings against a median of 42.4 — 1.8 times more concentrated than the median. Across 27 quarterly filings FHLC has become more concentrated: it behaved like 36.2 at 2019-10-31 and 25.3 at 2026-04-30. Between the 2026-01-31 and 2026-04-30 filings 23 positions were added and 15 dropped; 6.2% of the weight moved.

Each sentence is read from the fund's own SEC filing; the class median is computed across the comparable equity funds on this site. Nothing here is a view on the fund.

Between 2019-10-31 and 2026-04-30, FHLC went from behaving like 36.2 equally weighted positions to 25.3 — 30% fewer, while its top ten went from 43.26% to 50.67% of net assets. Read across the funds on the concentration-over-time table.

One row per filed reporting period, newest first, read from EDGAR. Quarterly because that is the public filing cadence. Rows marked * are published but held out of the comparison above; the methodology page says when and why.

The 15 largest of 336 positions in FHLC's Form N-PORT, weight as a share of net assets, securities-lending collateral excluded. Every position, every quarter: FHLC.csv.gz.

Share of FHLC's own investments by the issuer country the filer reported (incorporation, not revenue). Each country links to every fund that holds it.

Monthly total returns from Item B.5 of FHLC's own filings, 81 months on record. Not computed here and not from a price feed.

Cross-checked against a series computed separately from prices: median difference 0.06 percentage points over 81 months, which is roughly the distributions. Every month with the filing it came from: FHLC.json · all funds.

329 positions became 337: 23 added (0.3% of the fund at the later date), 15 dropped (0.9% at the earlier date). Half the sum of all weight changes, a turnover proxy: 6.2%. Positions are matched on identifiers, so a security whose identifier changed shows as one drop and one add. Every filing of FHLC compared this way, as a feed: changes.xml · all funds: filings received.

New: Terns Pharmaceuticals Inc (0.05%), Erasca Inc (0.03%), Capricor Therapeutics Inc (0.03%), Alumis Inc (0.03%), Kodiak Sciences Inc (0.02%), EyePoint Inc (0.02%). Gone: Exact Sciences Corp (0.30%), Hologic Inc (0.25%), Avidity Biosciences Inc (0.12%), Amicus Therapeutics Inc (0.06%), Arcellx Inc (0.03%), Avadel Pharmaceuticals PLC (0.03%).

99.85% equity, 0.15% short-term investment as filed; 100.0% carried at a quoted market price (fair-value level 1). Categories and levels are the filer's; what a low level-1 share does and does not mean is in the measure's page.

A position count cannot describe a fund that uses derivatives, because a swap is filed at its unrealised gain, not its exposure. These are the notionals the fund itself reported, against net assets of $2.85B. Notional of an interest-rate or currency swap is not equity exposure.

Full detail for every fund that files derivatives: leverage.json (CC BY 4.0).

Every measured equity fund lined up by how many holdings it behaves like; these sit either side of FHLC (23.5). Same filings, same arithmetic. Position in this list says nothing about which fund is better.